Monetize NIH Gene Therapy Database via Pharma Intelligence Subscription
- Organization
- NIH public grant database (RePORTER) containing detailed technical specifications of funded projects
- Sector
- Pharmaceutical business development teams desperate for early-stage gene therapy deal flow
- Location
- Location unspecified
Source reference
Executive summary
Current state
NIH awarded $311,049 Phase I STTR funding to OUTFLOWGEN LLC for a first-in-class CRISPR glaucoma therapy, creating a predictable commercial gap where scientific validation exists but commercialization infrastructure is absent. The structural asymmetry is between NIH's ability to fund early science and small biotechs' inability to navigate the regulatory and capital requirements for clinical development.
Market catalyst
NIH RePORTER contains granular technical data on thousands of funded gene therapy projects (CRISPR guides, delivery methods, disease targets) but this data is unstructured and not organized for commercial intelligence. Pharma BD teams spend millions on consultants to find early-stage assets, but lack systematic access to this publicly funded pipeline.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.